Wegovy’s success triggered a pharma gold rush, forecasting a potential industry’s biggest-ever blockbuster treatments.
Novo has vaulted into the limelight as Wegovy and another related medicine for diabetes, Ozempic, proved they could help people shed unwanted weight by curbing their appetite. For now, it’s restricting starter doses for Wegovy — which can help overweight people lose about 15% of their body weight — to safeguard supplies for people in the US who are already on the medicine, the company said.
“Overall a strong set of numbers from Novo Nordisk – driven by Wegovy,” Brian Godsk Borsting, a credit analyst at Danske Bank A/S, said in a note.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: